Anke J Lakerveld
Overview
Explore the profile of Anke J Lakerveld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gelderloos A, Lakerveld A, Schepp R, Nicolaie M, van Beek J, Beckers L, et al.
Clin Transl Immunology
. 2024 Jul;
13(8):e1521.
PMID: 39071109
Objectives: Increasing evidence suggests that Fc-mediated antibody effector functions have an important role in protection against respiratory viruses, including SARS-CoV-2. However, limited data are available on the potential differences in...
2.
Lakerveld A, Gelderloos A, Schepp R, de Haan C, Van Binnendijk R, Rots N, et al.
Clin Exp Immunol
. 2023 Aug;
214(1):79-93.
PMID: 37605554
Respiratory syncytial virus (RSV) infections are a major cause of bronchiolitis and pneumonia in infants and older adults, for which there is no known correlate of protection. Increasing evidence suggests...
3.
Binding of respiratory syncytial virus particles to platelets does not result in their degranulation
Lakerveld A, van Erp E, van Kasteren P
Access Microbiol
. 2023 Aug;
5(7).
PMID: 37601435
Respiratory syncytial virus (RSV) is a major cause of severe respiratory infection in infants and the elderly. The mechanisms behind severe RSV disease are incompletely understood, but a dysregulated immune...
4.
Heida R, Akkerman R, Jacob Silva P, Lakerveld A, Ortiz D, Bigogno C, et al.
J Control Release
. 2023 Apr;
357:264-273.
PMID: 37015293
Respiratory viruses including the respiratory syncytial virus (RSV) aggravate the global burden of virus-inflicted morbidity and mortality. Entry inhibitors are a promising class of antiviral drugs for combating these viruses,...
5.
Noordermeer T, van Asten I, Schutgens R, Lakerveld A, Koekman C, Hage K, et al.
Blood Adv
. 2022 Mar;
6(11):3347-3351.
PMID: 35255501
No abstract available.
6.
Yu X, Lakerveld A, Imholz S, Hendriks M, ten Brink S, Mulder H, et al.
mSphere
. 2020 Sep;
5(5).
PMID: 32878928
Respiratory syncytial virus (RSV) is increasingly recognized for causing severe morbidity and mortality in older adults, but there are few studies on the RSV-induced immune response in this population. Information...
7.
van Erp E, Lakerveld A, de Graaf E, Larsen M, Schepp R, Hipgrave Ederveen A, et al.
Clin Transl Immunology
. 2020 Feb;
9(2):e1112.
PMID: 32099650
Objectives: Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants, and there is no vaccine available. In early life, the most important contributors...
8.
Schmidt D, Lakerveld A, Heitink-Polle K, Bruin M, Vidarsson G, Porcelijn L, et al.
Vox Sang
. 2020 Feb;
115(4):323-333.
PMID: 32080872
Background: In adult immune thrombocytopenia (ITP), an acquired autoimmune bleeding disorder, anti-platelet autoantibody testing may be useful as a rule-in test. Childhood ITP has different disease characteristics, and the diagnostic...
9.
van Erp E, Lakerveld A, Mulder H, Luytjes W, Ferwerda G, van Kasteren P
Viruses
. 2019 Jun;
11(6).
PMID: 31163619
Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract disease requiring hospitalization in infants. There are no market-approved vaccines or antiviral agents available, but a...